Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism, and its role in chronic inducible urticaria.
Back
Special Report: Remibrutinib, an Oral BTKi, for Chronic Inducible Urticaria
Adam Friedman, MD, and Andrea Nguyen, PA, break down the approval of remibrutinib in symptomatic dermographism.
Special Report: Remibrutinib, an Oral BTKi, for Chronic Inducible Urticaria
Episodes
All
All
Advertisement
Advertisement
Trending on HCPLive
1
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
2
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
3
Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
4
Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY
5